Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 4
2015 5
2016 5
2017 3
2018 3
2019 5
2020 6
2021 3
2022 3
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity.
Khan S, Zhang X, Lv D, Zhang Q, He Y, Zhang P, Liu X, Thummuri D, Yuan Y, Wiegand JS, Pei J, Zhang W, Sharma A, McCurdy CR, Kuruvilla VM, Baran N, Ferrando AA, Kim YM, Rogojina A, Houghton PJ, Huang G, Hromas R, Konopleva M, Zheng G, Zhou D. Khan S, et al. Among authors: thummuri d. Nat Med. 2019 Dec;25(12):1938-1947. doi: 10.1038/s41591-019-0668-z. Epub 2019 Dec 2. Nat Med. 2019. PMID: 31792461 Free PMC article.
Cellular senescence and radiation-induced pulmonary fibrosis.
He Y, Thummuri D, Zheng G, Okunieff P, Citrin DE, Vujaskovic Z, Zhou D. He Y, et al. Among authors: thummuri d. Transl Res. 2019 Jul;209:14-21. doi: 10.1016/j.trsl.2019.03.006. Epub 2019 Mar 27. Transl Res. 2019. PMID: 30981698 Free PMC article. Review.
Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity.
Lv D, Pal P, Liu X, Jia Y, Thummuri D, Zhang P, Hu W, Pei J, Zhang Q, Zhou S, Khan S, Zhang X, Hua N, Yang Q, Arango S, Zhang W, Nayak D, Olsen SK, Weintraub ST, Hromas R, Konopleva M, Yuan Y, Zheng G, Zhou D. Lv D, et al. Among authors: thummuri d. Nat Commun. 2021 Nov 25;12(1):6896. doi: 10.1038/s41467-021-27210-x. Nat Commun. 2021. PMID: 34824248 Free PMC article.
Co-targeting BCL-XL and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice.
Khan S, Kellish P, Connis N, Thummuri D, Wiegand J, Zhang P, Zhang X, Budamagunta V, Hua N, Yang Y, De U, Jin L, Zhang W, Zheng G, Hromas R, Hann C, Zajac-Kaye M, Kaye FJ, Zhou D. Khan S, et al. Among authors: thummuri d. Cell Death Discov. 2023 Jan 2;9(1):1. doi: 10.1038/s41420-022-01296-8. Cell Death Discov. 2023. PMID: 36588105 Free PMC article.
Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-XL-Specific Degrader DT2216.
Thummuri D, Khan S, Underwood PW, Zhang P, Wiegand J, Zhang X, Budamagunta V, Sobh A, Tagmount A, Loguinov A, Riner AN, Akki AS, Williamson E, Hromas R, Vulpe CD, Zheng G, Trevino JG, Zhou D. Thummuri D, et al. Mol Cancer Ther. 2022 Jan;21(1):184-192. doi: 10.1158/1535-7163.MCT-21-0474. Epub 2021 Oct 19. Mol Cancer Ther. 2022. PMID: 34667112 Free PMC article.
Discovery of a Novel BCL-XL PROTAC Degrader with Enhanced BCL-2 Inhibition.
Pal P, Thummuri D, Lv D, Liu X, Zhang P, Hu W, Poddar SK, Hua N, Khan S, Yuan Y, Zhang X, Zhou D, Zheng G. Pal P, et al. Among authors: thummuri d. J Med Chem. 2021 Oct 14;64(19):14230-14246. doi: 10.1021/acs.jmedchem.1c00517. Epub 2021 Sep 17. J Med Chem. 2021. PMID: 34533954 Free PMC article.
XP-524 is a dual-BET/EP300 inhibitor that represses oncogenic KRAS and potentiates immune checkpoint inhibition in pancreatic cancer.
Principe DR, Xiong R, Li Y, Pham TND, Kamath SD, Dubrovskyi O, Ratia K, Huang F, Zhao J, Shen Z, Thummuri D, Daohong Z, Underwood PW, Trevino J, Munshi HG, Thatcher GRJ, Rana A. Principe DR, et al. Among authors: thummuri d. Proc Natl Acad Sci U S A. 2022 Jan 25;119(4):e2116764119. doi: 10.1073/pnas.2116764119. Proc Natl Acad Sci U S A. 2022. PMID: 35064087 Free PMC article.
34 results